Ignite Creation Date:
2025-12-24 @ 12:34 PM
Ignite Modification Date:
2025-12-27 @ 10:07 PM
Study NCT ID:
NCT01709461
Status:
UNKNOWN
Last Update Posted:
2012-10-18
First Post:
2012-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 12}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2012-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-06', 'lastUpdateSubmitDate': '2012-10-16', 'studyFirstSubmitDate': '2012-10-14', 'studyFirstSubmitQcDate': '2012-10-16', 'lastUpdatePostDateStruct': {'date': '2012-10-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-10-18', 'type': 'ESTIMATED'}}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Parkinson Disease']}, 'descriptionModule': {'briefSummary': 'the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '30 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* subjects who are willing to contiue this treatment.\n* subjects who took part in the TVP 1012/501 clinical trail.\n\nExclusion Criteria:\n\n* subjects who didn't take part in the TVP 1012/501 clinical trail."}, 'identificationModule': {'nctId': 'NCT01709461', 'briefTitle': 'Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial', 'organization': {'class': 'OTHER', 'fullName': 'Rabin Medical Center'}, 'officialTitle': 'Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial', 'orgStudyIdInfo': {'id': 'RD 06 - 12'}}, 'contactsLocationsModule': {'locations': [{'zip': '49100', 'city': 'Petach Tiqva', 'state': 'Central District', 'country': 'Israel', 'contacts': [{'name': 'Ruth Djaldetti, Professor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rabin Medical Center Beilinson Campus'}], 'centralContacts': [{'name': 'Ruth Djaldetti, Professor', 'role': 'CONTACT', 'email': 'ruthdjal@clalit.org.il', 'phone': '972-9378218/9'}, {'name': 'Yaniv roditi, Msc', 'role': 'CONTACT', 'email': 'yar@clalit.org.il', 'phone': '972-39236843'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rabin Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}